Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
Total Valuation
Dianthus Therapeutics has a market cap or net worth of $1.32B. The enterprise value is $411.31M.
Market Cap$1.32B
Enterprise Value$411.31M
Share Statistics
Dianthus Therapeutics has 39,816,223 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding39,816,223
Owned by Insiders<0.01%
Owned by Institutions52.87%
Financial Efficiency
Dianthus Therapeutics’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -28.62%.
Return on Equity (ROE)-0.24
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-28.62%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee79.94K
Profits Per Employee-1.09M
Employee Count78
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Dianthus Therapeutics is ―. Dianthus Therapeutics’s PEG ratio is 0.12.
PE Ratio―
PS Ratio116.48
PB Ratio2.06
Price to Fair Value2.06
Price to FCF-9.28
Price to Operating Cash Flow-14.27
PEG Ratio0.12
Income Statement
In the last 12 months, Dianthus Therapeutics had revenue of 6.24M and earned -84.97M in profits. Earnings per share was -2.55.
Revenue6.24M
Gross Profit6.24M
Operating Income-101.86M
Pretax Income-84.97M
Net Income-84.97M
EBITDA-101.45M
Earnings Per Share (EPS)-2.55
Cash Flow
In the last 12 months, operating cash flow was -109.52M and capital expenditures -106.00K, giving a free cash flow of -109.63M billion.
Operating Cash Flow-109.52M
Free Cash Flow-109.63M
Free Cash Flow per Share-2.75
Dividends & Yields
Dianthus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.22
52-Week Price Change83.07%
50-Day Moving Average36.70
200-Day Moving Average24.95
Relative Strength Index (RSI)70.82
Average Volume (3m)1.00M
Important Dates
Dianthus Therapeutics upcoming earnings date is Mar 19, 2026, TBA (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateMar 19, 2026
Ex-Dividend Date―
Financial Position
Dianthus Therapeutics as a current ratio of 15.22, with Debt / Equity ratio of 0.24%
Current Ratio15.22
Quick Ratio15.22
Debt to Market Cap<0.01
Net Debt to EBITDA0.21
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Dianthus Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Dianthus Therapeutics EV to EBITDA ratio is -6.95, with an EV/FCF ratio of -9.00.
EV to Sales113.06
EV to EBITDA-6.95
EV to Free Cash Flow-9.00
EV to Operating Cash Flow-9.02
Balance Sheet
Dianthus Therapeutics has $402.61M in cash and marketable securities with $1.28M in debt, giving a net cash position of $401.33M billion.
Cash & Marketable Securities$402.61M
Total Debt$1.28M
Net Cash$401.33M
Net Cash Per Share$10.08
Tangible Book Value Per Share$10.58
Margins
Gross margin is 93.57%, with operating margin of -1633.74%, and net profit margin of -1362.77%.
Gross Margin93.57%
Operating Margin-1633.74%
Pretax Margin-1362.77%
Net Profit Margin-1362.77%
EBITDA Margin-1627.14%
EBIT Margin-1633.74%
Analyst Forecast
The average price target for Dianthus Therapeutics is $69.15, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$69.15
Price Target Upside56.84% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast-42.64%
EPS Growth Forecast-39.78%